Endo International PLC

Endo International — Corporate Update (September 2015)

19 slides from Endo International's corporate update, Sep 28, 2015

  1. Slide 1: Endo International plc Company Update

    Exhibit 99.2 Endo International plc Company Update September 28, 2015 ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains information relating to the acquisition of Par by Endo that includes or is based on “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as a

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAPFinancial Measures This presentation refers to non-GAAP financial measures of Endo, including Adjusted EBITDA, adjusted diluted earnings per ordinary share from continuing operations, adjusted gross margin, adjusted operating expenses, adjusted interest expense and adjusted effective tax rat

  4. Slide 4: Par Pharmaceutical Acquisition: Compelling Strategic & Financial Rationale

    Par Pharmaceutical Acquisition: Compelling Strategic & Financial Rationale Strategically expands product portfolio, R&D pipeline, capabilities and long-term growth drivers Adds extensive range of dosage forms and delivery systems Focus on specialized, market leading products Designed to accelerate E

  5. Slide 5: Endo + Par: A Transformational Combination

    Endo + Par: A Transformational Combination Company Revenue ~2.9bn ~1.3bn Pro forma 2014 (2014) Revenue: ~$4.2bn Pro forma 2014 Adj. EBITDA (2014) ~$1.2bn ~$434mn Adj. EBITDA: ~$1.6bn Employees ~4,500 ~1,800 ~6,300 Expansion of branded Strong performance Operational and generic portfolio from portfol

  6. Slide 6: Qualitest + Par: A Leader in Specialty Generics

    Qualitest +Par: A Leader in Specialty Generics Business Generics 2014 Revenue: ~$1.1bn 2014 Revenue: ~$1.3bn Pro forma 2014 (2014) (+56% from 2013) (+19% from 2013) Revenue: ~$2.4bn Employees ~1,750 ~1,800 ~3,550 New York Connecticut Global Manufacturing Manufacturing Alabama Facilities North Caroli

  7. Slide 7: Addition of Par Generics Pipeline: Driving Near- and Long-Term Opportunities

    Addition of Par Generics Pipeline: Driving Near-and Long-Term Opportunities Anticipated Launches and Filings: 2016 2019– $16B market value $13B market value 46 Total 66 Total 8 FTF 12 FTF $8B market value $4B market value 2016 & 2017 2018 & 2019 Total Pipeline contains 47 potential FTF / FTM opportu

  8. Slide 8: 2015-2016: Anticipated Product Launches Provide Near-Term Earnings Visibility

    2015-2016: Anticipated Product Launches Provide Near-Term Earnings Visibility Anticipated Market Value Competitive Product Brand Launch (~$mm, LTM) Landscape Dutasteride/ 4Q 2015 Jalyn® $90 FTF Tamsulosin 1H 2016 RivastigminePatch* Exelon® $600 Multiple strengths July 2016 RosuvastatinTabs Crestor®

  9. Slide 9: 2017-2019: Robust Pipeline to Drive Long-Term Growth

    2017-2019: Robust Pipeline to Drive Long-Term Growth Market Value Selected Product Launches Brand Competitive Landscape (~$mm, LTM) Ciprofloxacin/ Dexmethasone Ciprodex® $400 FTF Adapalene& Benzoyl Peroxide Gel 0.1-2.5% Epiduo® $350 Limited competition Amphetamine Salts ER Capsules Adderal® $900 Lim

  10. Slide 10: Q3 2015 Financial Guidance (Continuing Operations)

    Q3 2015 Financial Guidance (Continuing Operations*) Measure Q32015 Revenues $720M -$740M Adjusted Interest Expenses** ~$95M AdjustedEffective Tax Rate 2% to 4% Weighted Average Diluted Shares Outstanding** 210M ** NOTE: as discussed around Q2 2015 results, the inclusion of pre-close financing activi

  11. Slide 11: 2015 Financial Guidance (Continuing Operations)

    2015 Financial Guidance (Continuing Operations*) Measure Prior 2015 Updated 2015 Guidance Guidance Revenues $2.90B -$3.00B $3.22B -$3.27B Adjusted Gross Margin 64% to 65% ~64% AdjustedOperating Expense to Revenue Ratio 23% to 24% ~21.5% Adjusted Interest Expenses ~$310M ~$375 AdjustedEffective Tax R

  12. Slide 12: 2016 Financial Guidance (Continuing Operations)

    2016 Financial Guidance (Continuing Operations*) 2016: Estimated Adjusted Diluted EPS of $5.85 to $6.15 In 2016, Endo is strongly positioned for: Double-digit revenue growth across our business Strong and rapid synergy capture from the Par acquisition Continued progression and execution of tax strat

  13. Slide 13: Appendix

    Appendix ©2015 Endo Pharmaceuticals Inc. All rights reserved.

  14. Slide 14: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Reconciliation of Projected GAAP Diluted Earnings Per Share from Continuing Operations to Adjusted Diluted Earnings Per Share from Continuing Operations Guidance for the Year Ending December 31, 2015 Lower End of Range Upper End of Range Projected GAAP diluted ear

  15. Slide 15: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Reconciliation of Projected GAAP Diluted Earnings Per Share from Continuing Operations to Adjusted Diluted Earnings Per Share from Continuing Operations Guidance for the Year Ending December 31, 2016 Lower End of Range Upper End of Range Projected GAAP diluted ear

  16. Slide 16: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Par Pharmaceuticals Adjusted EBITDA, Reconciliation Table for the Year Ending December 31, 2014 (Successor) Statement of Operations Data: (Unaudited) ($ in Thousands) ($105,517) 108,409 (72,993) and amortization 213,564 -up(a) 9,031 152,494 90,107 4,269 5,413 7,46

  17. Slide 17: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures (a) Represents the charge associated with acquisitions for acquired inventory which was increased to its estimated selling price, less the cost of disposal and a reasonable profit allowance for the selling effort (the “inventory step-up”), as required under GAAP.

  18. Slide 18: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures Endo International plc Adjusted EBITDA, Reconciliation Table for the Year Ending December 31, 2014 Statement of Operations Data: (Unaudited) ($ in Thousands) Net loss attributable to Endo International plc $ (721,319) Income tax (401,840) Interest expense, net 227

  19. Slide 19: Endo International plc Company Update

    Endo International plc Company Update September 28, 2015 ©2015 Endo Pharmaceuticals Inc. All rights reserved.

Endo International — Corporate Update (September 2015) on 6ix